信迪利单抗注射液联合化疗在晚期胃癌患者中的应用效果  

The Application Effect of Sintilimab Injection Combined with Chemotherapy in Advanced Gastric Cancer Patients

作　　者：张培培 ZHANG Peipei(Nantong Tongzhou People's Hospital,Nantong 226300,China)

机构地区：[1]南通市通州区人民医院,江苏南通226300

出　　处：《中外医学研究》2025年第6期29-32,共4页CHINESE AND FOREIGN MEDICAL RESEARCH

摘　　要：目的:探讨信迪利单抗注射液联合化疗在晚期胃癌患者中的应用效果及对免疫水平的影响。方法:选取2020年1月—2024年2月南通市通州区人民医院收治的82例晚期胃癌患者作为研究对象,根据信封法分为对照组和观察组,每组各41例。对照组采用化疗治疗(替吉奥联合奥沙利铂),观察组联合信迪利单抗注射液治疗,比较两组肿瘤标志物、T淋巴细胞水平及安全性。结果:观察组的总体客观缓解率(ORR)和疾病控制率(DCR)高于对照组,差异有统计学意义(P<0.05);两组治疗3个疗程后肿瘤标志物水平降低,差异有统计学意义(P<0.05);观察组癌胚抗原(CEA)、糖类抗原19-9(CA19-9)、糖类抗原242(CA242)、甲胎蛋白(AFP)低于对照组,差异有统计学意义(P<0.05);两组治疗3个疗程后免疫水平得到改善,观察组CD3^(+)、CD4^(+)及CD4^(+)/CD8^(+)高于对照组,CD8+低于对照组,差异有统计学意义(P<0.05);两组治疗3个疗程毒副反应发生率比较,差异无统计意义(P>0.05)。结论:信迪利单抗注射液联合化疗用于晚期胃癌患者中,能提高患者治疗效果,降低肿瘤标志物水平,提高患者免疫水平,未增加毒副反应发生率。Objective:To investigate the effect of Sintlimab injection combined with chemotherapy in patients with advanced gastric cancer and influence on immunity level.Method:A total of 82 patients with advanced gastric cancer in Nantong Tongzhou People's Hospital of City from January 2020 to February 2024 were selected as the subjects,and they were divided into two groups by envelope method,with 41 cases in each group.The control group was treated with chemotherapy(Teggio combined with oxaliplatin),while the observation group was treated with sindillimab injection.Tumor markers,T lymphocyte levels and safety of the two groups were compared.Result:The overall objective response rate(ORR)and disease control rate(DCR)of observation group were higher than those of control group,and the difference was statistically significant(P<0.05).After 3 courses of treatment,the level of tumor markers decreased between the two groups,and the difference was statistically significant(P<0.05).The levels of Carcinoembryonic antigen(CEA),carbohydrare antigen 19-9(CA19-9),carbohydrare antigen 242(CA242),alpha-fetoprotein(AFP)in the observation group were lower than those in the control group,with statistical significance(P<0.05).The levels of immunity were improved after three courses of treatment.The levels of CD3^(+),CD4^(+),and CD4^(+)/CD8^(+) in the observation group were higher than those in the control group,with statistical significance(P<0.05).The levels of CD8+in the observation group were lower than those in the control group,with statistical significance(P<0.05).And there was no statistical difference in the incidence of toxicities during the three courses of treatment(P>0.05).Conclusion:Sindilimab injection combined with chemotherapy can improve the therapeutic effect of patients with advanced gastric cancer,reduce the level of tumor markers,and improve the immune level of patients,but does not increase.

关 键 词：信迪利单抗注射液 化疗 晚期胃癌 免疫水平 肿瘤标志物 毒副反应 

分 类 号：R735.2[医药卫生—肿瘤]